{"id":"NCT02139644","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","officialTitle":"A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Low-dose or or Mid-dose Inhaled Corticosteroid Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2014-05-15","resultsPosted":"2017-04-12","lastUpdate":"2021-11-12"},"enrollment":787,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"FS MDPI","otherNames":["fluticasone propionate","inhaled corticosteroid","salmeterol xinafoate","β2 adrenoceptor agonist"]},{"type":"DRUG","name":"Fp MDPI","otherNames":["fluticasone propionate","inhaled corticosteroid"]},{"type":"DRUG","name":"Placebo MDPI","otherNames":["inert powder"]},{"type":"DRUG","name":"albuterol/salbutamol","otherNames":["short-acting β2-adrenergic agonists"]},{"type":"DRUG","name":"Beclomethasone dipropionate","otherNames":["QVAR"]}],"arms":[{"label":"FS MDPI 100 / 12.5 mcg","type":"EXPERIMENTAL"},{"label":"FS MDPI 50 / 12.5 mcg","type":"EXPERIMENTAL"},{"label":"Fp MDPI 100 mcg","type":"EXPERIMENTAL"},{"label":"Fp MDPI 50 mcg","type":"EXPERIMENTAL"},{"label":"Placebo MDPI","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when administered over 12 weeks in patients 12 years of age and older with persistent asthma.\n\nStudy drug and placebo was supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants performed spirometry at every visit. Each participant was given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) was dispensed at each visit, if needed, as determined by the investigational center personnel.","primaryOutcome":{"measure":"Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12","timeFrame":"Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours","effectByArm":[{"arm":"FS MDPI 100 / 12.5 mcg","deltaMin":0.408,"sd":0.0465},{"arm":"FS MDPI 50 / 12.5 mcg","deltaMin":0.399,"sd":0.0479},{"arm":"Fp MDPI 100 mcg","deltaMin":0.254,"sd":0.0434},{"arm":"Fp MDPI 50 mcg","deltaMin":0.268,"sd":0.0457},{"arm":"Placebo MDPI","deltaMin":0.074,"sd":0.0487}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0076"},{"comp":"OG001 vs OG003","p":"0.0322"},{"comp":"OG000 vs OG004","p":"0.0000"},{"comp":"OG001 vs OG004","p":"0.0000"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":140,"countries":["United States","Canada","Czechia","Hungary","Poland","Russia","South Africa","Ukraine"]},"refs":{"pmids":["36472162","28763243","27216137"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":126},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection"]}}